Latest Conference Coverage

Outlining the Clinical and Radiological Features of NMOSD, MOGAD

Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.

Clinical, Radiological Features of NMOSD and MOGAD: Amy Kunchok, MD

The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]

Comorbidity Patterns Among Brain Disorders: Imad Najm, MD

The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]

NeuroVoices: Darcy Krueger, MD, PhD, on Ganaxolone, Genetics, and Drug Development for Tuberous Sclerosis

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space.

Areas for Future Development in Epilepsy Research: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]

Untapping the Potential of Seizure Applications, Telemedicine

Jessica Fesler, MD, MEd, staff epileptologist, Cleveland Clinic, offered insight on the future of seizure apps and how if improved, they could alter the treatment of patients with epilepsy.

Shifting to a Holistic Approach to Treat Developmental Epileptic Encephalopathies

The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.

Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

Recent Advances, Future Developments in Epilepsy Surgery: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute spoke on the latest advances with epilepsy surgery, as well as what still needs to be learned. [WATCH TIME: 5 minutes]

Live Reactions From AES 2021: Trends, Encouraging Research, and Expert Presentations

Leaders in the epilepsy space provided their thoughts on the most promising aspects, initial takeaways, and dominating conversations at the 2021 American Epilepsy Society annual meeting.

Takeaways From AES 2021: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed poignant presentations from the 2021 American Epilepsy Society Annual Meeting. [WATCH TIME: 7 minutes]

Cenobamate’s Efficacy Profile in Treating Seizures: William Rosenfeld, MD

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed numerous presentations from AES 2021 that bolstered cenobamate’s known efficacy and safety profile. [WATCH TIME: 7 minutes]

Potential of Neuropalliative Care Evaluated for Patients With Drug-Resistant Epilepsy

Investigators suggest further studies to better determine is NPC had measurable benefits for patient quality of life.

Cenobamate Offers Unique Benefit for Surgically Refractory Epilepsy

Across all surgical procedures, the percentage of patients with seizure freedom for at least 12 months ranged from 20% to 35.7% for patients receiving cenobamate.

Vaccination and Seizure Risk in Dravet Syndrome: Veronica Hood, PhD, MS

The scientific director at the Dravet Syndrome Foundation commented on the concern associated with vaccination in this patient population, noting that investigators have not observed an exacerbated risk profile with the COVID-19 vaccines. [WATCH TIME: 2 minutes]

Perampanel Shows Real-World Benefit in Epilepsy With Comorbid Intellectual Disability

In total, 6.4% of those with intellectual disability achieved seizure freedom and 37.5% had at least a 50% responder rate after treatment with perampanel.

Cementing an Understanding of Managing Seizures in Elders With Epilepsy

While typically thought of as a disease that affects younger populations, Rebecca O’Dwyer, MD, stressed the importance and nuances of caring for older adults with epilepsy.

COVID-19 Vaccination in Patients with Dravet Syndrome: Veronica Hood, PhD, MS

The scientific director at the Dravet Syndrome Foundation discussed a recent survey asking caregivers about the experiences of patients with DS following COVID-19 vaccination. [WATCH TIME: 3 minutes]

VNS Implantation, Dietary Therapies Reduce Seizures in Children With TSC, DRE

Findings presented at AES 2021 included data from children with tuberous sclerosis complex and drug refractory epilepsy who were not candidates for epilepsy surgery.

Ganaxolone Associated With Decreased Seizure Frequency in Patients With CDD, LGS

Four out of 6 patients with CDKL5 deficiency disorder and comorbid Lennox-Gastaut syndrome had a decrease in frequency of major motor seizures when treated with ganaxolone.

CBTip Demonstrates Pronounced Results in Psychogenic Nonepileptic Seizures

Half of the patients who were on a flexible, longer-term Cognitive Behavioral Therapy-informed psychotherapy treatment schedule demonstrated improvements in seizure frequency by more than 50%.

Perampanel Further Demonstrates Efficacy, Safety in Large Real-World Analysis

At the 12-month mark, more than 64% of patients had remained on perampanel, with an overall mean retention time of 10.8 months.

Exploring the Benefits of CBT for Psychogenic Non-Epileptic Seizures: Becky Tilahun, PhD

The clinical psychologist at Cleveland Clinic discussed the potential of using cognitive behavioral therapy for treatment of psychogenic non-epileptic seizures on cognitive behavioral therapy. [WATCH TIME: 3 minutes]

Perampanel Effective, Well-Tolerated in Lennox-Gastaut Syndrome

Findings were presented at AES 2021, with 56.7% of patients reporting a 50% or greater reduction in seizure frequency.

Prednisolone Improves Seizure Outcomes in Infantile Spasms After Vigabatrin Failure

More than two-thirds of patients who received prednisolone after showing no response to vigabatrin demonstrated complete electroclinical response at 2 weeks, with most sustaining response at 6 weeks.

Patient Feedback on Telehealth: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the positive feedback from patients when discussing telehealth. [WATCH TIME: 4 minutes]

Masupirdine Improves Agitation and Aggression in Alzheimer Disease

A phase 3 trial has been initiated to further study masupirdine’s effect on agitation in patients with Alzheimer dementia.

Future Integration, Coverage for Telemedicine in Multiple Sclerosis: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed the necessary data to support telemedicine’s integration into clinical care. [WATCH TIME: 4 minutes]

Lecanemab Reduces Amyloid in Patients With Early Alzheimer Disease

Data show a clinical benefit via a reduction in brain amyloid as early as 3 months in the open-label extension period.

Choosing Therapies for Patients With MS: Devon Conway, MD

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the process of choosing a therapy for patients with multiple sclerosis. [WATCH TIME: 4 minutes]